Immix Biopharma, Inc. (NASDAQ:IMMX) Stock Rated “Moderate Buy” by Wall Street Analysts

Immix Biopharma, Inc. (NASDAQ:IMMX – Get Free Report) has received a consensus rating of “Moderate Buy” from the nine ratings firms that are presently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation and eight have given a buy recommendation to the company. The average 12-month price target among brokers that have covered the stock in the last year is $24.29.

IMMX has been the subject of several research reports. HC Wainwright raised their target price on Immix Biopharma from $20.00 to $25.00 and gave the stock a “buy” rating in a research report on Monday, August 10th. Weiss Ratings restated a “sell (d-)” rating on shares of Immix Biopharma in a research note on Thursday, October 15th. Mizuho increased their price objective on shares of Immix Biopharma from $15.00 to $26.00 and gave the company an “outperform” rating in a research note on Tuesday, September 15th. Morgan Stanley reaffirmed an “overweight” rating on shares of Immix Biopharma in a report on Tuesday. Finally, Citigroup reiterated a “market outperform” rating on shares of Immix Biopharma in a research report on Wednesday, September 30th.

Read Our Latest Report on Immix Biopharma

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. Legal & General Group Plc bought a new position in Immix Biopharma during the second quarter worth about $41,000. Nisa Investment Advisors LLC bought a new stake in shares of Immix Biopharma in the 3rd quarter valued at approximately $52,000. Compass Financial Management LLC bought a new stake in shares of Immix Biopharma in the 2nd quarter valued at approximately $56,000. Allworth Financial LP bought a new stake in shares of Immix Biopharma in the 2nd quarter valued at approximately $75,000. Finally, Everhart Financial Group Inc. bought a new stake in shares of Immix Biopharma in the 2nd quarter valued at approximately $103,000. Institutional investors and hedge funds own 11.26% of the company’s stock.

Immix Biopharma Trading Down 2.4%

Shares of IMMX stock opened at $8.15 on Tuesday. The stock has a 50 day moving average of $11.49 and a two-hundred day moving average of $10.20. Immix Biopharma has a 12 month low of $2.85 and a 12 month high of $15.10. The company has a market capitalization of $583.04 million, a P/E ratio of -9.26 and a beta of 0.24.

Immix Biopharma (NASDAQ:IMMX – Get Free Report) last announced its quarterly earnings data on Friday, August 7th. The company reported ($0.18) earnings per share for the quarter, missing the consensus estimate of ($0.17) by ($0.01). Sell-side analysts predict that Immix Biopharma will post -0.76 earnings per share for the current fiscal year.

About Immix Biopharma

(Get Free Report)

Immix Biopharma, Inc is a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with difficult-to-treat cancers and other serious diseases. The company’s research and development activities are centered on engineered immune-cell treatments intended to target malignant cells.

Its lead product candidate is NXC-201, an investigational autologous chimeric antigen receptor T-cell (CAR-T) therapy designed to target B-cell maturation antigen (BCMA). NXC-201 is being evaluated in clinical studies for relapsed or refractory multiple myeloma and relapsed or refractory AL amyloidosis, a rare blood disorder in which abnormal plasma cells produce misfolded proteins.

Immix Biopharma was founded in 2012 and is headquartered in Los Angeles, California.

Further Reading

Analyst Recommendations for Immix Biopharma (NASDAQ:IMMX)

Receive News & Ratings for Immix Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immix Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.